Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:1963 |
Name | fallopian tube carcinoma |
Definition | A fallopian tube cancer that is located_in the fallopian tube. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer fallopian tube cancer fallopian tube carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00989651 | Phase I | Bevacizumab + Veliparib Carboplatin Paclitaxel Cisplatin | Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Completed | USA | 0 |
NCT01145430 | Phase I | Pegylated liposomal doxorubicin + Veliparib | Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer | Completed | USA | 0 |
NCT01239732 | Phase III | Bevacizumab + Carboplatin + Paclitaxel | A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer | Completed | TUR | SWE | SVN | SVK | ROU | POL | NLD | LVA | LTU | ITA | ISR | IRL | HUN | GRC | FRA | EST | ESP | DNK | CHE | CAN | BRA | BGR | AUT | ARG | 13 |
NCT01248962 | Phase II | Carboplatin | Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer | Completed | USA | 0 |
NCT01281514 | Phase I | Carboplatin + Everolimus + Pegylated liposomal doxorubicin | Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | Completed | USA | 0 |
NCT01504126 | Phase I | Propranolol | Beta-Blocker / Ovarian | Completed | USA | 0 |
NCT01519869 | Phase I | Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma | Completed | USA | 0 | |
NCT01607905 | Phase I | Selinexor | Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer | Completed | USA | DNK | CAN | 0 |
NCT01669798 | Phase II | Nintedanib | BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer | Completed | USA | 0 |
NCT01849874 | Phase III | Binimetinib | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Terminated | USA | SWE | POL | NOR | NLD | ITA | IRL | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BEL | AUT | AUS | 0 |
NCT01936974 | Phase II | Bevacizumab + Cisplatin + Gemcitabine Bevacizumab + Gemcitabine + Oxaliplatin Bevacizumab + Carboplatin + Gemcitabine Bevacizumab + Gemcitabine | (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma | Terminated | USA | 0 |
NCT01974765 | Phase II | Enzalutamide | Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies | Completed | USA | 0 |
NCT02033616 | Phase II | Ovapuldencel-T | Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas | Unknown status | USA | 0 |
NCT02042430 | Phase I | Epacadostat | INCB024360 Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | 0 |
NCT02059265 | Phase II | Dasatinib | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer | Terminated | USA | 0 |
NCT02101775 | Phase II | Gemcitabine Adavosertib + Gemcitabine | Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | CAN | 1 |
NCT02121990 | Phase I | Bevacizumab + Cisplatin + Olaparib + Paclitaxel | Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | Completed | USA | 0 |
NCT02122185 | Phase II | Metformin Carboplatin + Docetaxel + Paclitaxel | Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | 0 |
NCT02122861 | Phase I | ID-LV305 | A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 | Completed | USA | 0 |
NCT02166905 | Phase Ib/II | Poly ICLC Rasdegafusp alfa Epacadostat | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | Completed | USA | 0 |
NCT02178722 | Phase Ib/II | Epacadostat + Pembrolizumab | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Completed | USA | 0 |
NCT02188550 | Phase II | Everolimus + Letrozole | Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer | Unknown status | USA | 0 |
NCT02195973 | Phase Ib/II | Paclitaxel + Sonidegib | Phase IB/II Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer | Completed | USA | 0 |
NCT02208375 | Phase Ib/II | Capivasertib + Olaparib Olaparib + Vistusertib | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian | Active, not recruiting | USA | 0 |
NCT02275039 | Phase I | MVAp53 Gemcitabine | p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer | Completed | USA | 0 |
NCT02283658 | Phase II | Everolimus + Letrozole | Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | Completed | USA | 0 |
NCT02316834 | Phase I | Talazoparib | POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer | Completed | USA | 0 |
NCT02387125 | Phase I | CMB305 | A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 | Terminated | USA | 0 |
NCT02431559 | Phase Ib/II | Aldoxorubicin + Durvalumab + Motolimod | A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated | Completed | USA | CHE | 0 |
NCT02440425 | Phase II | Paclitaxel Pembrolizumab | Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer | Completed | USA | 0 |
NCT02459301 | Phase I | Monalizumab | Dose-Ranging Study of IPH2201 in Patients With High Grade Serious CA of Ovarian, Fallopian Tube or Peritoneal Origin | Completed | CAN | 0 |
NCT02470585 | Phase III | Carboplatin Paclitaxel Veliparib | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Terminated | USA | POL | NZL | ISR | GBR | ESP | DNK | BRA | AUS | 2 |
NCT02485990 | Phase Ib/II | Olaparib Tremelimumab | Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) | Terminated | USA | 0 |
NCT02537444 | Phase II | Acalabrutinib Pembrolizumab | ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer (KEYNOTE191) | Completed | USA | 0 |
NCT02571725 | Phase Ib/II | Olaparib + Tremelimumab | PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT02608684 | Phase II | Cisplatin + Gemcitabine + Pembrolizumab | A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer | Completed | USA | 0 |
NCT02611024 | Phase Ib/II | Irinotecan + Lurbinectedin | Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors | Recruiting | USA | ITA | FRA | ESP | DEU | CHE | 0 |
NCT02657928 | Phase II | Letrozole + Ribociclib | Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer | Completed | USA | 0 |
NCT02659241 | Phase I | Adavosertib | A Pilot Study of Induction Wee1 Inhibition in Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT02661815 | Phase I | Paclitaxel + Ricolinostat Bevacizumab | A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer | Terminated | USA | 0 |
NCT02764333 | Phase II | Durvalumab + TPIV 200 | TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer | Completed | USA | 0 |
NCT02833506 | Phase I | NY-ESO-1 peptide vaccine + Sirolimus NY-ESO-1 peptide vaccine | Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Withdrawn | USA | 0 |
NCT02834975 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab | Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). | Terminated | USA | 0 |
NCT02889900 | Phase II | Cediranib + Olaparib | Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO) | Completed | USA | 0 |
NCT02922764 | Phase I | RGX-104 Ipilimumab + RGX-104 Nivolumab + RGX-104 Carboplatin + Pembrolizumab + Pemetrexed Disodium + RGX-104 | A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma | Active, not recruiting | USA | 0 |
NCT02953457 | Phase II | Durvalumab + Olaparib + Tremelimumab | Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation | Active, not recruiting | USA | 0 |
NCT03017131 | Phase I | Aldesleukin + Cyclophosphamide + Decitabine + Letetresgene autoleucel | Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | 0 |
NCT03018405 | Phase Ib/II | NKR-2 cells | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) | Unknown status | USA | BEL | 0 |
NCT03029403 | Phase II | Cyclophosphamide + Maveropepimut-S + Pembrolizumab | Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer | Active, not recruiting | CAN | 0 |
NCT03054298 | Phase I | HuCART-meso cells Cyclophosphamide | CAR T Cells in Mesothelin Expressing Cancers | Completed | USA | 0 |
NCT03054909 | Phase I | Nogapendekin alfa inbakicept | QUILT-2.021: Phase I of IP Followed by SQ ALT-803 for Ovarian Cancer | Completed | USA | 0 |
NCT03206047 | Phase Ib/II | Atezolizumab + Guadecitabine Atezolizumab Atezolizumab + Guadecitabine + Rasdegafusp alfa | Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | 0 |
NCT03206645 | Phase I | Carboplatin + Paclitaxel + Unesbulin | PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy | Completed | USA | 0 |
NCT03246074 | Phase I | Fostamatinib + Paclitaxel | Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer | Completed | USA | 0 |
NCT03394885 | Phase Ib/II | Atezolizumab + Carboplatin + Paclitaxel | Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer (AdORN) | Completed | USA | 0 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Completed | USA | 0 |
NCT03531645 | Phase II | Fulvestrant + Palbociclib | Fulvestrant Plus Palbociclib in Women With Advanced Low Grade Serous Carcinoma | Active, not recruiting | USA | 0 |
NCT03596281 | Phase I | Pegylated liposomal doxorubicin + Pembrolizumab Bevacizumab + Pembrolizumab | Pembrolizumab in Combination With Bevacizumab and Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer (PEMBOV) | Completed | FRA | 0 |
NCT03598270 | Phase III | Carboplatin + Gemcitabine Niraparib Carboplatin + Pegylated liposomal doxorubicin Atezolizumab + Carboplatin + Pegylated liposomal doxorubicin Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel Atezolizumab + Niraparib | Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA) | Completed | ITA | FRA | ESP | DEU | BEL | 0 |
NCT03675893 | Phase II | Abemaciclib + LY3023414 Abemaciclib + Letrozole Abemaciclib + Letrozole + Metformin Abemaciclib + Letrozole + LY3023414 Abemaciclib + Letrozole + Zotatifin | RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT03691376 | Phase I | Melphalan NY-ESO-1 TCR CD4- CD34+ HSC Aldesleukin Autologous NY-ESO-1-specific CD8-positive T cells | Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Terminated | USA | 0 |
NCT03735589 | Phase Ib/II | alphaDC1 + NK-like CTLs | Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Withdrawn | USA | 0 |
NCT03839524 | Phase I | TG4050 | A Trial Evaluating TG4050 in Ovarian Carcinoma. | Active, not recruiting | USA | FRA | 0 |
NCT03924245 | Phase Ib/II | Entinostat Entinostat + Olaparib | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers | Terminated | USA | 0 |
NCT03959761 | Phase Ib/II | Nivolumab | Tolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian Carcinoma (ICONIC) | Unknown status | FRA | 0 |
NCT04205227 | Phase Ib/II | ENB003 + Pembrolizumab | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | Active, not recruiting | USA | AUS | 0 |
NCT04570839 | Phase Ib/II | BMS-986207 + COM701 + Nivolumab Nivolumab | COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | Completed | USA | 0 |
NCT04657068 | Phase Ib/II | ART0380 + Gemcitabine ART0380 Gemcitabine | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | Recruiting | USA | GBR | FRA | ESP | 0 |
NCT04706962 | Phase I | TH1902 | TH1902 in Patients With Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT04787289 | Phase II | Bevacizumab | A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer | Recruiting | CAN | 0 |
NCT04861181 | FDA approved | Niraparib | NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients. (NIRAPK) | Recruiting | FRA | 0 |
NCT04918186 | Phase II | BA3021 + Durvalumab Durvalumab + Mecbotamab Vedotin | Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC) | Recruiting | USA | CAN | 0 |
NCT05116189 | Phase III | Bevacizumab + Docetaxel Bevacizumab + Paclitaxel + Pembrolizumab Bevacizumab + Docetaxel + Pembrolizumab Bevacizumab + Paclitaxel | Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) | Active, not recruiting | USA | TUR | POL | NZL | NOR | NLD | ITA | ISR | IRL | GBR | FRA | FIN | DNK | DEU | CAN | BRA | BEL | AUS | 7 |
NCT05257408 | Phase III | Nab-paclitaxel Nab-paclitaxel + Relacorilant | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer | Active, not recruiting | USA | POL | ITA | ISR | HUN | GBR | FRA | ESP | CAN | BRA | BEL | AUS | ARG | 1 |
NCT05261490 | Phase Ib/II | Pegylated liposomal doxorubicin + TTI-622 | Study of TTI-622 in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer | Terminated | USA | 0 |
NCT05358639 | Phase I | Navitoclax + Olaparib | Combination of Olaparib and Navitoclax in Women With HGSC and TNBC | Recruiting | CAN | 0 |
NCT05394675 | Phase I | DS-9606a | A Study of DS-9606a in Patients With Advanced Solid Tumors | Recruiting | USA | GBR | 0 |
NCT05465941 | Phase II | PLX038 | PLX038 for the Treatment of Patients With Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | Recruiting | USA | 0 |
NCT05564377 | Phase II | Selumetinib Binimetinib + Fulvestrant Binimetinib + Palbociclib Nilotinib + Paclitaxel Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin Panitumumab + Sotorasib Binimetinib Fulvestrant Olaparib Olaparib + Selumetinib Alpelisib + Olaparib Neratinib Neratinib + Palbociclib Fluorouracil + Leucovorin + Oxaliplatin Ipatasertib + Paclitaxel | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Recruiting | USA | 1 |
NCT05601700 | Phase III | Carboplatin + Paclitaxel Letrozole | Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial) (LEPRE) | Recruiting | ITA | 0 |
NCT05601752 | Phase II | ADP-A2M4CD8 | ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) | Recruiting | USA | GBR | FRA | ESP | CAN | 0 |
NCT05836324 | Phase I | INCA33890 | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DNK | CHE | 0 |
NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
NCT06028932 | Phase II | Sacituzumab govitecan-hziy | A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients | Recruiting | USA | 0 |